BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Based on the current evidence, we hypothesised that treatment naïve CML CD34+ cells possess a gene expression programme independent of the BCR-ABL1 TK, which allows them to persist following TKI treatment and that the components of this programme could be targeted to eradicate the leukaemic clone.